GEN News Highlights

Which Life Science Leaders Under 40 Are Shaking Up the Industry the Most?

(Page
1
of
1)

If you combine the old clichés that the “future belongs to the young” and “the future is now” you could really be talking about today’s life science industry. For one of the most striking recent developments in the evolution of the biotech business is the number of under-40 individuals who are now at the helm of biopharmaceutical companies. Gone are the days when it was virtually axiomatic that a man or a woman (mostly men actually) who had spent many years working at major pharmaceutical companies would be hired for any open spot as president or CEO at a biotech company.

Now, having grown up in a completely interconnected world and weaned on the internet and other modern wonders of technology, increasing numbers of young people have the smarts, the drive, and the background to accept the challenge of running a biotech company and making profitability the goal. Taking their cues from Bill Gates and Steve Jobs, their motto seems to be that vision can trump experience.

GEN is putting together a list of the “Top Life Science Leaders Under 40” and we want your input. Please send your candidate to pbartell@genengnews.com for our listing and provide us with the name, age, position, company affiliation, and reason why you believe your nomination should be on our list. If your suggested candidate makes the list, you could win a $10 coffee gift card. We welcome your participation!

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.